To present a case of malignant reninoma with pulmonary metastasis and an ATRX mutation, emphasizing the significance of olaparib therapy in achieving local control.
Key Findings:
The patient had an ATRX mutation (p.G1964*, VAF 23.73%) associated with malignant reninoma.
Olaparib therapy led to the resolution of the renal recurrent tumor but not the pancreatic lesions or pulmonary metastases, highlighting the complexity of treatment.
Tumor heterogeneity was evident, necessitating further investigation into combination therapies to improve treatment outcomes.
Interpretation:
Olaparib demonstrates potential for local control in ATRX-mutated malignant reninoma, but varied responses at metastatic sites underscore the complexity of treatment and the need for tailored approaches.
Limitations:
The rarity of malignant reninoma limits generalizability of findings.
The case highlights the need for further research into combination therapies to address tumor heterogeneity and potential biases in treatment response.
Conclusion:
This case emphasizes the importance of molecular profiling in rare tumors and the potential of targeted therapies like olaparib in precision medicine, guiding treatment decisions.
